Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter]

Drug Des Devel Ther. 2025 Jan 6:19:65-66. doi: 10.2147/DDDT.S512114. eCollection 2025.
No abstract available

Publication types

  • Comment